Sharda Cropchem Limited has informed the Exchange about Investor Presentation
12th May, 2023
To,
National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051
BSE Limited Phiroze Jeejeebhoi Tower, Dalal Street, Mumbai – 400 001
Trading Symbol: SHARDACROP
Scrip Code: 538666
Subject: Investors / Analyst’s Presentation for the Quarter and Year ended 31st March, 2023
Dear Sir/Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing herewith the presentation to be made to the Investors/Analysts on the Financial Results of the Company for the quarter and year ended 31st March, 2023.
The presentation is also being uploaded on the website of the Company www.shardacropchem.com the Listing Regulations.
in accordance with Regulation 46 of
We request you to take the same on record.
Yours Sincerely,
__________________ Jetkin Gudhka Company Secretary & Compliance Officer
Encl.: As above
Investor Presentation May 2023
Safe Harbor
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sharda Cropchem Limited (the “Company”), have been prepared solely for
information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection
with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed
information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty,
express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This
Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this
Presentation is expressly excluded
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively
forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions
that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets,
the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion,
technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as
other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation.
The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties
included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.
2
About Sharda Cropchem Limited
“We are a fast-growing global agrochemicals company with a peer position in the generic crop protection chemicals industry. Our vast and growing library of dossiers and IPRs provide us solid foundations for growth in the global marketplace, especially in Advanced Markets such as Europe, North America and Latin America. It equips us with the ability to operate in a diversified range of formulations and generic active ingredients space globally”
Agrochemical Focused Company
Intellectual Property (IP) driven company engaged in marketing and distribution of wide range formulations and generic active ingredients
Asset Light Business Model
Efficiently channelizing time and resources for strengthening core competency of identifying generic molecules and registration opportunities which offer scalable growth with limited capital requirements
Large Pipeline of Registrations*
Procured 2,821 registrations. Additionally, it has filed 1,143 applications for registrations globally pending at different stages
Diversified Sourcing Arrangements
Enduring relationship with multiple manufacturers and formulators enables to source and supply formulations or generic active ingredients at competitive prices
Consistently Increasing Global Presence
With diversified range of product portfolio, Company has grown by expanding business operations in 80+ countries, across Europe, NAFTA, Latin America and ROW
Widespread Distribution Network
Presence in the entire agrochemical value chain with 500 third party distributors and 400+ sales force serving the Company’s esteemed clientele in 80+ countries
Company’s apt domain knowledge and experience gives substantial competitive advantage for expanding business in existing markets and new geographies
*As on 31st March 2023
5
Asset Light Business Model
Overall Agrochemical Value Chain
Sharda’s Operating Area
√
√
√
√
Basic & Applied Research
Identification
Registration
Active Ingredient Manufacturing
Formulation & Packaging
Marketing & Distribution
SHARDA CROPCHEM’s ASSET LIGHT BUSINESS MODEL
Focus on identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulations through third-party distributors and/or own sales force
Manufacturing of AIs and formulations is outsourced
Highly flexible operating model resulting in • Overall cost competitiveness
• Efficient management of fluctuating market
demand across various geographies
• Offering wide range of formulations and AIs
Acts as a key differentiator from an innovator company, allowing the Company to save its capital, time and resources on R&D
6
Increasing Global Presence having a Widespread Distribution
Presence 80+ countries
across Europe, NAFTA, LATAM & RoW
Global Resource Deployment 500+
Over the years, we’ve built a strong brand franchise within our global markets; we are benefiting through the economies of scale in our portfolio and leveraging value of our supply chain to deliver value to our customers across geographies
Company has gained a great deal from globalization, including new customers and diverse geocentric revenue streams. Over the years, we have mastered flexibility and adopted innovative ways to grow our business overseas
Distributors 525+
CAPEX incurred in FY23* Rs. 355 Cr.
In addition to newer markets, the wide global presence has allowed us to find new, specialised sales and local marketing talent.
Successfully adopted a factory-to- farmer approach to become a one- stop solution provider to our global customers
* Plus related revenue expenditure on registrations
Strengthening and widening the sales force in Europe, USA, Canada, Mexico, Colombia, South Africa, India, and rest of the world, in addition to third party distributors with a goal to enhance its presence in the agrochemical value chain
It enables the Company to penetrate its formulations and generic active ingredients in various countries backed by the third-party distributors and presence of its own sales force
7
The Sharda Advantage
THE SHARDA ADVANTAGE
Global Reach
Wide Product Range
Healthy relationships with suppliers
Quality with Affordability
Faster Sales Service
One Stop Solution Provider for Crop Care Products
8
Way Forward
Forward Integration - Build Sales Force
Expand & Strengthen Distribution Presence
➢ Leverage market presence and execution capabilities
➢ Expand geographical reach using existing library of
➢ Adopt the factory to farmer approach and be a one stop
solution provider
➢ Strategy on ground in different regions of NAFTA, Europe, LATAM and other key markets in ROW
dossiers
➢ Two-fold strategy of further penetrating existing markets
and entering new markets
Continual Investment in Product Registrations
Focus on Operational Efficiencies
➢ Continue to identify generic molecules going off patent
➢ Accelerated focus on revenue generating investments
➢ Investing in preparing dossiers and seeking registrations
➢ Margin improvements
in own name
➢ Better cost management and eliminate NVAs
9
Industry Outlook and Growth Drivers
Global crop protection chemicals market value (In Billion USD) – CAGR of 3.5%
59.7
8.1
42.0
62.8
77.0
43.7
53.0
5.3
2020
3.9
0.5
8.4
5.9
4.3
0.6
2025e
10.2
7.7
5.4
0.8
2030e
Herbicide
Fungicide
Insecticide
Nematicide
Molluscicide
INDUSTRY DRIVERS
1
2
3
A growing population: the global population is set to increase by 1.2 billion by 2030 and 2 billion by 2050, while the middle class will more than double to 4.9 billion by 2030
A growing middle class fuels demand for increased food and protein production, which in turn drives demand for grain to support growth
Fewer arable acres per capita means that products need to continue to maximise farmer yields; arable land is expected to decrease from half an acre per person today to less than one- third of an acre per person by 2050
Primary Research, Secondary Research, Magna Information Centre
10
Experienced Management
Mr. Ramprakash V. Bubna Chairman & Managing Director
Mr. Ashish Bubna Whole Time Director
Mr. Manish Bubna Whole Time Director
Mr. Ashok Vashisht Chief Financial Officer
•
•
•
Holds a Bachelor’s Degree of Technology in Chemical Engineering from IIT, Bombay
He has over 53 years of experience in chemicals, agrochemicals and related businesses
He is responsible for the Company’s overall business operations and strategy
•
•
•
•
Holds a Bachelor’s Degree in Commerce from the University of Mumbai
Over 30 years of experience in marketing of chemicals, agrochemicals and related businesses.
Instrumental in strategizing early investment in product registrations and building the library of product dossiers.
Responsible for marketing, procurement, registrations and logistics functions of the agrochemical business.
•
•
•
•
Holds a Bachelor’s Degree in Chemical Engineering from the Department of Chemical Technology, Bombay University.
Over 28 years of experience in chemicals, agrochemicals and related businesses
Spearheaded the Company’s foray into the conveyor belt and general chemicals business
Also oversees the information technology, logistics and documentation functions of the Company
•
•
He is Fellow member of Chartered Institute of Management Accountants UK & accredited CGMA, Fellow member of CPA Australia, Fellow member of The Institute of Cost Accountants of India and Associate member of The ICSI. He has also done DipIFR from ACCA UK and qualified Independent Director from IICA
25+ years of rich professional corporate experience in global and Indian MNCs in the field of Strategy, M&A, Financial Management, Direct & Indirect Taxation, Strategic Cost Management, Project Management, Statutory Audits & Internal Audits, Governance & Risk Management
11
Q4 FY23 Financial Highlights
Q4 FY23: Segment Wise Highlights
Agrochemical Segment
Non Agrochemical Segment
TOTAL REVENUES
87%
1,243
89%
1,316
13%
191
11%
% of Revenue
100%
100%
166
1,434
1,482
Cr.
Q4FY22
Q4FY23
Q4FY22
Q4FY23
Q4FY22
Q4FY23
+6%
-13%
+3%
On Consolidated Basis
13
Q4 FY23: Region Wise Breakup (Agrochemical Segment)
Europe
NAFTA Region
49%
611
+46%
68%
893
39%
487
-37%
23%
309
Q4FY22
Q4FY23
Q4FY22
Q4FY23
LATAM Region
9%
110
-58%
4%
47
RoW
+88%
5%
67
3%
36
Q4FY22
Q4FY23
Q4FY22
Q4FY23
% of Revenue
Cr.
TOTAL REVENUES (Agrochemical Segment)
1,243
1,316
Q4FY22
Q4FY23
+6%
On Consolidated Basis
14
Q4 FY23: Region Wise Breakup (Non Agrochemical Segment)
Europe
NAFTA Region
28%
54
-64%
12%
19
57%
110
+1%
67%
111
Q4FY22
Q4FY23
Q4FY22
Q4FY23
LATAM Region
5%
10
-50%
3%
5
RoW
+78%
18%
31
9%
17
Q4FY22
Q4FY23
Q4FY22
Q4FY23
% of Revenue
Cr.
TOTAL REVENUES (Non - Agrochemical Segment)
191
166
Q4FY22
Q4FY23
-13%
On Consolidated Basis
15
Q4 FY23: Financial Highlights
Revenues & GP Margin
EBITDA & EBITDA Margin*
Cr.
29.2%
31.6%
1,434
1,482
Revenue growth led by better product mix & price realization
Gross Margins have improved by 240 basis points due to increased sales in Europe and better margins
+3%
22.1%
21.0%
317
312
Q4FY22
Q4FY23
Q4FY22
Q4FY23
- 2%
EBITDA and EBIDTA Margins were impacted due to general inflation and increase in local freight costs
Profit Before Tax & PBT Margin
Profit After Tax & PAT Margin
14.8%
212
17.2%
255
PBT has grown by 20% on account of increased Gross Profit Margins and a favourable impact of forex gain during the quarter
+20%
11.7%
169
13.4%
199
PAT has grown by 18%, led by better product mix & price realization. A favourable impact of forex gain during the quarter also helped to improve margins
+18%
Q4FY22
Q4FY23
Q4FY22
Q4FY23
* EBITDA is excluding IA & IAUD write-off (Rs. 5.4 cr. in Q4 FY23; Rs. 17.8 cr. in Q4 FY22)
On Consolidated Basis
16
FY23 Financial Highlights
FY23 Segment Wise Highlights
Agrochemical Segment
Non Agrochemical Segment
TOTAL REVENUES
84%
3,004
83%
3,348
16%
576
17%
697
% of Revenue
100%
100%
3,580
4,045
Cr.
FY22
FY23
FY22
FY23
FY22
FY23
+11%
+21%
+13%
On Consolidated Basis
18
FY23: Region Wise Breakup (Agrochemical Segment)
Europe
NAFTA Region
46%
1,379
+29%
53%
1,774
38%
34%
-2%
1,153
1,125
FY22
FY23
FY22
FY23
LATAM Region
10%
315
-24%
7%
239
RoW
+34%
6%
209
5%
156
FY22
FY23
FY22
FY23
% of Revenue
Cr.
TOTAL REVENUES (Agrochemical Segment)
3,004
3,348
FY22
FY23
+11%
On Consolidated Basis
19
FY23: Region Wise Breakup (Non Agrochemical Segment)
Europe
NAFTA Region
31%
179
-24%
20%
136
50%
287
+47%
61%
424
FY22
FY23
FY22
FY23
LATAM Region
5%
27
+35%
5%
37
RoW
+23%
14%
101
14%
82
FY22
FY23
FY22
FY23
% of Revenue
Cr.
TOTAL REVENUES (Non - Agrochemical Segment)
697
576
FY22
FY23
+21%
On Consolidated Basis
20
Impact of weakened Euro to the Dollar in FY23
USD / Euro Price Chart
1.11
Unprecedented depreciation of Euro to the USD led to forex losses of Rs. 82 crores in H1 FY23
The Euro has rebounded to some extent and this has led to forex gain of Rs. 24 crores in H2 FY23
1.09
1.15
1.1
1.05
1
0.95 01-04-2022
16-05-2022
30-06-2022
14-08-2022
28-09-2022
12-11-2022
27-12-2022
10-02-2023
27-03-2023
0.98
Euro Dollar Exchange Rate
Major currencies have depreciated to the USD in the first six months of the financial year due to the ongoing war between Russia & Ukraine. In the second half of FY23, we have seen a rebound of these currencies.
Over 53% of FY23 Sales from Agrochemical business have been to the Europe whereas majority of the Company’s Raw Material is imported from China and payments are done in US Dollar.
This has impacted the Company’s Gross Margin and overall profitability as the Euro had considerably depreciated against the dollar.
21
FY23: Financial Highlights
Revenues & GP Margin
EBITDA & EBITDA Margin*
Cr.
30.2%
3,580
29.3%
4,045
Revenue growth led by better product mix and price realization.
Gross Margins have been impacted by weakening of €/$ leading to increased input cost mainly in H1 FY23
+13%
20.4%
17.6%
729
713
FY22
FY23
FY22
FY23
EBITDA and EBIDTA Margins were impacted due to lower GP Margins driven by weakening of €/$ leading to increased input cost, general inflation and strengthening of global workforce to support future growth.
- 2%
Profit Before Tax & PBT Margin
Profit After Tax & PAT Margin
13.0%
464
10.6%
431
- 7%
PBT was mainly impacted by increased forex losses of Rs. Rs. 58 crores in FY23
Excluding Forex Losses, PBT has grown by 2% in FY23
9.8%
349
8.5%
342
- 2%
FY22
FY23
FY22
FY23
* EBITDA is excluding IA & IAUD write-off (Rs. 5.4 cr. in Q4 FY23; Rs. 17.8 cr. in Q4 FY22 ; Rs. 11.9 cr. in FY23; Rs. 29.2 cr. in FY22
PAT de-grew by 2% to Rs. 342 crores for FY23, mainly due to lower profits in H1 FY23
Recommended Final Dividend of Rs. 3 per equity share in addition to interim dividend of Rs. 3 per equity shares, aggregating to Rs. 6 per equity share for FY23
On Consolidated Basis
22
Strong Balance Sheet
Working Capital (in Days)
RoCE
RoE
89 days
104 days
25.7%
19.8%
20.8%
16.5%
138
121
72
152
140
91
Mar-22
Mar-23
Mar-22
Mar-23
Total Equity
Total Debt
Cash & Cash Equivalents
Mar-22
Mar-23
Inventory Days
Recievable Days
Creditor Days
Rs. 2,232 crores
Rs. 3 crores
Rs. 328 crores*
Rs. 1,912 crores as on Mar’22
Rs. 38 crores as on Mar’22
Rs. 300 crores as on Mar’22
* Includes FDs of Rs. 114 crores clubbed in Non Current Other Financial Assets
ROE: PAT/Avg. Equity, ROCE: EBIT/Avg. Capital Employed [(Capital Employed = Equity + Total Debt)]
On Consolidated Basis
23
Annexure
Q4 & FY23 Financial Highlights
Particulars
Revenue from Operations
COGS
Gross Profit
Gross Margin %
Employee Expenses
Other Expenses
EBITDA*
EBITDA Margin %
Forex (Gain)/Loss
Depreciation
Other Income
EBIT
EBIT Margin %
Finance Cost
PBT
PBT Margin
Tax Expense
PAT
PAT Margin %
Earnings Per Share (EPS) In Rs.
Q4 FY23
1,481.8
1,013.9
Q4 FY22
1,434.5
1,015.3
Y-o-Y
3%
467.9
31.6%
15.2
146.4
311.8
21.0%
-11.9
67.7
7.0
257.6
17.4%
2.5
255.1
17.2%
56.3
198.9
13.4%
22.0
419.2
29.2%
12.7
107.0
317.3
22.1%
9.2
71.7
2.7
221.2
15.4%
0.7
220.5
15.4%
43.5
177.0
12.3%
19.6
-2%
20%
16%
12%
FY23
4,045.2
2,860.8
1,184.4
29.3%
44.8
438.9
712.6
17.6%
57.6
248.1
40.3
435.3
10.8%
4.5
430.7
10.6%
88.8
342.0
8.5%
37.9
FY22
3,579.8
2,499.8
1,080.0
30.2%
44.2
336.4
728.6
20.4%
16.5
245.3
28.9
466.5
13.0%
2.2
464.2
13.0%
115.0
349.3
9.8%
38.7
Cr.
Y-o-Y
13%
-2%
-7%
-7%
-2%
* EBITDA is excluding IA & IAUD write-off (Rs. 5.4 cr. in Q4 FY23; Rs. 17.8 cr. in Q4 FY22 ; Rs. 11.9 cr. in FY23; Rs. 29.2 cr. in FY22)
On Consolidated Basis
25
Balance Sheet - Consolidated
EQUITY & LIABILITIES
Equity
Equity share capital Other equity Equity attributable to equity holders of the Company Non-controlling interests Total Equity
Non-current liabilities
Financial liabilities
Lease liabilities Trade payables
total outstanding dues of micro enterprises and small enterprises other than micro enterprises and small enterprises
Other financial liabilities Provisions Deferred tax liabilities (net) Total non-current liabilities
Current liabilities
Financial liabilities
Borrowings Lease liabilities Trade payables
total outstanding dues of micro enterprises and small enterprises other than micro enterprises and small enterprises
Other financial liabilities Other current liabilities Provisions Income Tax Provisions Total current liabilities Total Equity & Liabilities
Mar-23
Mar-22
ASSETS
Mar-23
Mar-22
Cr.
90.2 2141.8 2,232.0 0.4 2,232.4
90.2 1822.2 1,912.5 0.3 1,912.8
-
3.5
0.0 0.0 1.7 2.7 143.4 147.9
0.0 2.4 1.6 2.3 128.9 138.6
3.0 0.0
38.0 5.1
1.9 1375.7 431.4 78.1 61.4 19.1 1,970.6 4,350.8
8.8 1168.8 324.8 55.4 86.7 4.2 1,691.8 3,743.1
Non-current assets
Property, plant and equipment
Goodwill
Intangible assets
Intangible assets under development
Financial assets
Other Financial Assets
Deferred Tax Assets
Income tax assets (net)
Total non-current assets
Current assets
Inventories
Financial assets
Investments
Trade receivables
Cash and cash equivalents
Bank balance other than cash and cash equivalents
Loans
Other financial assets
Other current assets
Total current assets
Total Assets
5.0
0.0
663.0
203.9
140.6
7.9
72.3
14.4
0.0
577.4
212.2
11.2
4.9
71.6
1,092.7
891.7
1,134.3
892.8
31.9
1,833.3
176.4
5.5
0.0
28.7
48.1
3,258.2
4,350.8
134.4
1,540.0
56.7
109.3
0.5
49.9
67.9
2,851.5
3,743.1
26
Cash Flow Statement
Particulars (Rs. Cr.)
Profit Before Tax
Adjustments
Operating profit before working capital changes
Changes in working capital
Cash generated from operations
Direct taxes paid (net of refund)
Net Cash from Operating Activities
Net Cash from Investing Activities
Net Cash from Financing Activities
Exchange difference arising on conversion debited/ (credited) to foreign currency translation reserve (D)
Net Change in cash and cash equivalents
Opening Cash Balance
Effect of exchange rate changes on cash & cash equivalents held in foreign currencies
Closing Cash Balance
FY23
430.7
266.5
697.2
-303.7
393.5
-65.3
328.3
-145.2
-97.1
33.0
119.0
56.7
0.7
176.4
FY22
464.2
256.9
721.1
-379.2
341.9
-74.8
267.1
-207.9
-91.0
2.8
-28.9
85.6
0.0
56.7
27
Key Financial Performance Indices
Cr.
Revenue
EBITDA & EBITDA Margin*
Profit After Tax & PAT Margin
3,580
4,045
1,998
2,003
2,396
20.7%
18.5%
17.6%
19.0%
17.6%
11.2%
8.8%
8.2%
9.8%
8.5%
369
352
455
176
165
229
729
713
349
342
FY19
FY20
FY21
FY22
FY23
FY19
FY20
FY21
FY22
FY23
FY19
FY20
FY21
FY22
FY23
RoCE
RoE
Net Cash & Cash Equivalents^
25.7%
20.2%
20.8%
18.8%
13.9%
14.6%
12.3%
15.2%
19.8%
16.5%
336
269
276
262
325
FY19
FY20
FY21
FY22
FY23
FY19
FY20
FY21
FY22
FY23
FY19
FY20
FY21
FY22
FY23
* EBITDA is excluding IA & IAUD write-off
^ Total Cash & Cash Equivalents – Debt (Includes FDs of Rs. 114 crores clubbed in Non Current Other Financial Assets)
On Consolidated Basis
28
Historical Profit & Loss
Particulars
Revenue from Operations
COGS
Gross Profit
Gross Margin %
Employee Expenses
Other Expenses
EBITDA*
EBITDA Margin %
Forex (Gain)/Loss
Depreciation
Other Income
EBIT
EBIT Margin %
Finance Cost
PBT
Tax Expense
PAT
PAT Margin %
Earnings Per Share (EPS) In Rs.
* EBITDA is excluding IA & IAUD write-off
FY23
4,045.2
2,860.8
1,184.4
29.3%
44.8
438.9
712.6
17.6%
57.6
248.1
40.3
435.3
10.8%
4.5
430.7
88.8
342.0
8.5%
37.90
FY22
3,579.8
2,499.8
1,080.0
30.2%
44.2
336.4
728.6
20.4%
16.5
245.3
28.9
466.5
13.0%
2.2
464.2
115.0
349.3
9.8%
38.71
FY21
2,395.6
1,636.0
759.7
31.7%
37.3
305.5
455.2
19.0%
-19.9
170.4
45.9
312.2
13.0%
2.8
309.5
80.2
229.2
9.6%
25.40
FY20
2,003.0
1,388.8
614.3
30.7%
34.9
282.4
351.7
17.6%
15.1
137.1
42.1
186.8
9.3%
1.9
184.9
20.2
164.7
8.2%
18.25
Cr.
FY19
1,997.6
1,387.3
610.2
30.5%
33.5
250.1
368.8
18.5%
4.5
99.4
20.6
243.4
12.2%
8.4
235.0
58.7
176.3
8.8%
19.55
On Consolidated Basis
29
Balance Sheet – Equity & Liabilities
Equities & Liabilities Shareholder's Funds Equity and Share Capital Other Equity Non-controlling Interest Total Equity
Non-Current Liabilities Borrowings Trade Payables Lease Liabilities Other Financial Liabilities Provisions Deferred Tax Liabilities (net) Total Non-Current Liabilities
Current Liabilities Borrowings Lease Liabilities Trade Payables Other Financial Liabilities Other Current Liabilities Current Tax Liabilities Provisions Total Current Liabilities Total Equity & Liabilities
FY23
90.2 2141.8 0.4 2,232.4
- - - 1.7 2.7 143.4 147.9
3.0 - 1,377.6 431.4 78.1 19.1 61.4 1,970.6 4,350.8
FY22
90.2 1,822.2 0.3 1,912.8
- 2.4 3.5 1.6 2.3 128.9 138.6
38.0 5.1 1,177.6 324.8 55.4 4.2 86.7 1,691.8 3,743.1
FY21
90.2 1,524.1 0.3 1,614.6
- 2.4 8.4 3.2 3.0 92.9 109.9
67.8 4.5 806.8 149.1 58.0 3.2 50.0 1,139.4 2,863.9
FY20
90.2 1,312.6 0.3 1,403.1
0.1 2.4 - 13.1 2.7 69.3 87.5
0.0 - 686.7 89.7 54.4 1.5 24.4 856.7 2,347.2
Cr.
FY19
90.2 1,193.7 0.2 1,284.1
0.1 2.9 - 1.4 2.2 91.0 97.6
0.0 - 636.2 104.0 60.7 0.6 20.1 821.7 2,203.3
On Consolidated Basis
30
Balance Sheet - Assets
ASSETS
Assets
Non-Current Assets
Property, Plant and Equipment
Goodwill
Other Intangible assets
Intangible assets under development
Deferred Tax Assets (net)
Non-Current Tax Assets
Other financial assets
Total Non-Current Assets
Current Assets
Inventories
Investments
Trade Receivables
Cash & Cash equivalents
Other Bank balances
Loans
Other Financial Assets
Other Current Assets
Total Current Assets
Total Assets
FY23
FY22
FY21
FY20
FY19
Cr.
5.0
0.0
663.0
203.9
7.9
72.3
140.6
1,092.7
1,134.3
31.9
1,833.3
176.4
5.5
0.0
28.7
48.1
3,258.2
4,350.8
14.4
0.0
577.4
212.2
4.9
71.6
11.2
891.7
892.8
134.4
1,540.0
56.7
109.3
0.5
48.9
68.9
2,851.5
3,743.1
20.9
0.4
523.1
131.0
6.0
73.6
9.4
764.5
525.5
83.0
1,162.6
85.6
175.0
-
28.1
39.6
2,099.3
2,863.9
27.8
0.4
388.1
161.4
3.9
72.5
11.6
665.7
382.2
115.5
988.4
77.8
75.7
-
11.3
29.6
13.5
0.4
357.8
219.8
5.5
49.2
8.9
655.2
364.9
211.9
811.4
50.6
73.0
-
11.9
24.3
1,681.5
2,347.2
1,548.2
2,203.3
On Consolidated Basis
31
CSR Activities
CSR initiatives taken up by the Company are in the areas of Promoting Education, Healthcare, Eradicating Hunger, Empowerment of Women, Animal Welfare, Promotion of Sports and Rural Development Projects
Promoting Education
Animal Welfare
Medical Aid & Relief
32
THANK YOU
Company: Sharda Cropchem Limited
Investor Relation Advisors: Strategic Growth Advisors Pvt. Ltd.
CIN: L51909MH2004PLC145007
CIN: U74140MH2010PTC204285
Mr. Ashok Vashisht - CFO cfo@shardaintl.com Tel: +91 22 6678 2800
Mr. Deven Dhruva deven.dhruva@sgapl.net Tel: +91 98333 73300